A yellow Miyarisan box can tell you the brand, the tablet count and the name of its principal ingredient. A research paper can tell you something quite different: which preparation was studied, who received it and how the investigators analyzed their findings. Understanding where those two kinds of information meet—and where they do not—is the most useful starting point for this Japanese product.
For a concrete example, this guide uses Miyarisan Strong Miyarisan Tablets, 330 Count, available at Japan Pantry. We will look at the manufacturer's history, read the official Japanese label, explain its measurement units and examine the structure of selected human studies. The retail bottle is a label example, not a substitute for the preparations used in those studies.
The central distinction is simple: a familiar brand name does not make every product from that manufacturer interchangeable. The same is true of a microorganism's name. A connection between names is useful background, but evidence needs a much more precise match.
1. What can we verify about the 330-tablet bottle?
Start with identity rather than a promise. The official manufacturer is Miyarisan Pharmaceutical Co., Ltd. Its Japanese product information lists Strong Miyarisan tablets in 90-, 330- and 1,000-tablet packs. The 330-tablet size on our product page is therefore one of the packaging sizes in the manufacturer's own documentation. [1] [3]
The manufacturer describes the principal ingredient as Miyairi bacteria powder. The published label specifies 270 mg in nine tablets. That statement establishes an ingredient amount and its denominator. It does not, by itself, establish the number of viable organisms, a comparison with another preparation or a likely result for an individual reader. [4]
Swipe to compare →
| Question | What the sources establish | What that does not establish |
|---|---|---|
| Who makes it? | Miyarisan Pharmaceutical Co., Ltd. | Independent validation of every statement about the product. |
| Which pack is discussed here? | The 330-tablet retail listing, within the manufacturer's listed pack sizes. | That all Miyarisan preparations have the same composition. |
| What amount is disclosed? | 270 mg of Miyairi bacteria powder per nine tablets. | A disclosed CFU count or an equivalent amount of a research preparation. |
| What is the research connection? | Human papers examine preparations described as MIYAIRI 588 / CBM588. | That the papers directly tested this retail bottle. |
Keeping these boundaries visible makes the rest of the article more informative. It lets us discuss the manufacturer without turning company history into an outcome claim, and discuss research without implying that a shopper will reproduce a study participant's experience.
2. The Japanese manufacturer: a long history, not a shortcut around evidence
Miyarisan's own company timeline traces its work with Miyairi bacteria back to 1933. It records the start of industrial production in 1940 and the establishment of the Miyairi bacteria preparation research institute in 1947. The present company profile lists June 1947 as the company's establishment date. These are related milestones, not three competing dates for the creation of today's retail bottle. [1]
This distinction matters whenever a brand tells a heritage story. Discovery of an organism, production of an ingredient, establishment of a company and introduction of a particular package are different events. A bottle can belong to a long-running product family without its current packaging, formulation or intended audience being identical to every earlier version.
Swipe to compare →
| Year | Milestone in the company timeline | How to interpret it |
|---|---|---|
| 1933 | Discovery of Miyairi bacteria. | A starting point for the manufacturer's account of its bacterial research. |
| 1940 | Start of industrial production. | A production milestone, not the date of a trial on today's 330-tablet pack. |
| 1947 | Research institute established; company profile lists establishment in June. | An organizational milestone. |
| 2006 | Company name changed to Miyarisan Pharmaceutical Co., Ltd. | Explains the current manufacturer name. |
| 2018 | The timeline records a CBM plant and a research facility. | Evidence of facilities in the company's history, not a retail-product outcome. |
| 2023 | The timeline records expansion of its packaging building. | A manufacturing-capacity development. |
The source for this timeline is the manufacturer. That is an appropriate primary source for its corporate milestones, but it should be identified as such. Company history tells us who stands behind the label and how the organization describes its development; it cannot answer every question about a finished product's performance.
What the bacterial name adds—and what it leaves open
The manufacturer's English page refers to Clostridium butyricum MIYAIRI. The papers examined for this guide use the more specific names MIYAIRI 588 or CBM588. A species name identifies a broad biological category; an additional strain designation is a more specific identifier. A finished preparation adds another layer: the material containing the organism, its amount, its manufacturing specifications and the conditions under which it is used. [2] [5]
It would be too simple to collapse those layers into one. A useful reading habit is to ask three separate questions: what organism is named, what preparation contains it, and what exact preparation was studied? If the third answer is different from the retail product, the article needs to preserve that difference.
The English company page and the retail insert reviewed here do not supply the missing link by explicitly naming “588” on the retail label. That is a disclosure limit in the documents we examined, not proof that the product contains a different organism. The appropriate conclusion is that precise traceability has not been established from these sources—not that we can fill it in ourselves.
3. Why 270 mg is not a CFU count
The most easily misread number is 270 mg. On the manufacturer's insert, it applies to Miyairi bacteria powder in nine tablets, the denominator used for the adult label amount. It is not the amount in one tablet and it is not the weight of the whole tablet. Reading the denominator first avoids a ninefold error before any comparison with another label begins. [3] [4]
Dividing 270 mg by nine gives 30 mg of the stated powder per tablet. That is calculated arithmetic from the published label, not a separately reported laboratory measurement. It still tells us nothing about how many viable organisms are in that portion of powder. Two preparations with similar powder weights need not contain the same viable count.
Swipe to compare →
| Label item | Published information | Reading note |
|---|---|---|
| Ingredient amount | 270 mg of Miyairi bacteria powder in nine tablets. | Keep the nine-tablet denominator attached to the number. |
| Calculated per-tablet amount | 30 mg of the stated powder. | Calculated as 270 ÷ 9; not a CFU conversion. |
| Pack quantity | 330 tablets in the linked retail pack. | Count describes the package, not the concentration in each tablet. |
| Other listed ingredients | Lactose hydrate, corn starch, talc, crystalline cellulose, magnesium stearate and white sugar. | The ingredient list matters independently of the bacterial name. |
| Viable count | No CFU figure is supplied in the retail insert examined here. | Do not calculate an undisclosed count from powder weight. |
CFU stands for colony-forming units: a count based on viable organisms capable of producing colonies under the relevant test conditions. Milligrams measure mass. The two units answer different questions. A conversion would require information about the particular material and its viable count under specified conditions; there is no universal milligram-to-CFU equation.
Swipe to compare →
| Measurement or identifier | What it describes | Why it is not interchangeable |
|---|---|---|
| Tablet count | The number of units in a pack. | Does not describe ingredient concentration. |
| Powder mass, in mg | The weight of the specified ingredient material. | Does not disclose viable-organism count. |
| CFU | A viable count under the applicable assay conditions. | Is not a weight measurement. |
| Species or strain name | Biological identity at different levels of specificity. | Does not, alone, describe a finished preparation or its amount. |
What about the manufacturer's spore description?
The Japanese product page describes Miyairi bacteria as forming spores, a durable bacterial structure. This is useful context for the manufacturer's presentation of the ingredient. It is still not a numerical test of the linked bottle's viable count, an independent comparison against every other bacterial product, or an estimate of an individual reader's response. [3]
The same care applies to the Japanese label's market classification. The insert is a Japanese-market document. That does not decide the product's U.S. marketing status, and this guide does not attempt a U.S. regulatory assessment. The practical role of the insert here is to provide an identifiable source for the composition, directions and handling information we discuss.
4. Reading human research without turning it into a retail-product promise
Human evidence is more informative than a general brand story, but “there are human studies” is only the start of the discussion. We need to know the design, the preparation, the setting, the number of people and how much of the enrolled group remained in the analysis. The selected papers below are examples for learning those distinctions, not a systematic review or an estimate of the retail product's effects.
All three papers concern specialist clinical settings. They are not general shopping-population studies of the 330-tablet bottle. The 2025 paper used MIYARISAN BM sachets; the earlier papers also discuss CBM588 preparations in medical-care settings. Their clinical endpoints are not used here as reasons to buy the retail product. [5] [6] [7]
Swipe to compare →
| Selected paper | Reported study size | Design | Key reading limitation |
|---|---|---|---|
| 2025 | 398 enrolled. | Randomized crossover study with observation phases and blinded assessors. | Different preparation; no look-alike placebo; substantial loss to follow-up. |
| 2020 | 118 people in the retrospective cohort. | Review of existing clinical records in Japan. | Not randomized; background care and other differences can influence associations. |
| 2018 | 40 participants; 20 per group. | Randomized, open-label adjunctive study. | Small groups, no double blinding and concurrent care; not a retail-product study. |
A larger sample cannot repair a mismatch
The graph makes the range in sample sizes easy to see: 40 to 398 people. But a larger number cannot make a different preparation equivalent to the one on a store shelf. Nor can it remove the distinction between a randomized comparison and an observational association. These are different sources of uncertainty, and each needs its own question.
A randomized design helps address differences between groups at assignment. A retrospective study starts from existing care and records, so the reasons people received a preparation may be connected with the outcomes later observed. The 2018 paper randomized 20 people to an added CBM588 preparation and 20 to a control group, but its open-label design and small groups still require caution. “Open label” describes blinding; it does not mean there was no comparison group. [7]
The 2025 study: why follow-up and analysis population matter
The most recent paper enrolled 398 people, divided into groups of 200 and 198. Its first-year follow-up counts were 168 and 85, totaling 253. At the end of the full protocol, the counts were 111 and 85, totaling 196. Fewer than half of the original participants therefore completed the full protocol. These are follow-up counts, not measures of benefit. [5]
The paper reports both intention-to-treat and per-protocol analyses. Its first-year intention-to-treat comparisons of the two reported outcomes were not statistically significant; the per-protocol comparisons were more favorable. A summary that mentions only the favorable analysis leaves out an important part of the paper. [5]
Swipe to compare →
| Analysis question | What it means | What to check in this paper |
|---|---|---|
| Intention to treat | Analyze participants according to original assignment, including a method for missing observations. | The authors used imputation; results depend in part on assumptions about missing data. |
| Per protocol | Focus on participants who met the protocol and follow-up requirements for the relevant analysis. | First-year completers and full-protocol completers are not the same-sized group. |
| Loss to follow-up | Some originally enrolled participants do not provide the complete scheduled observations. | Dropout differed between the original groups, making selection and missing-data assumptions important. |
Loss to follow-up does not automatically invalidate a study. It does make the reasons for missing observations and the analysis assumptions more consequential. People who remain may differ from those who leave. Looking at the enrolled population alongside the completer population helps avoid mistaking a selected subset for the whole original group.
The paper also had no look-alike placebo during its observation phases, although assessors were blinded to assignment. It discloses that the manufacturer supplied the study preparation without charge and states that the company had no role in the study's design, data collection, analysis or manuscript preparation. Those details belong in a careful account of the methods and disclosures. [5]
The preparation is another decisive limitation. The study describes one-gram MIYARISAN BM packets containing 40 mg of CBM588 per gram, taken twice daily. That is a description of the study protocol—not a suggested regimen for the retail tablets. Comparing that powder number with the retail label's 270 mg would ignore differences in materials and specifications. The documents reviewed do not establish a valid equivalence.
For a shopper, the responsible takeaway is not a simplified positive or negative verdict on the brand. It is that this group of papers leaves a gap between research on particular preparations and a result for the exact retail bottle. That gap needs direct evidence or a documented equivalence, not a shared name.
5. A transparent price calculation—and its limits
At the time this guide was prepared, on October 8, 2026, our 330-tablet listing showed US$21.99. Dividing the bottle price by 330 gives approximately 6.7 U.S. cents per tablet. This is a simple allocation of the retail price, before shipping and any applicable taxes; it is not a measure of effect or of viable-organism content.
Price per tablet can help you understand the cost of a particular pack. It cannot tell you whether another product's tablet contains the same material, whether different preparations can be substituted, or whether a higher-priced item is better matched to your needs. Just as milligrams and CFU are different measurements, cost and research relevance are different comparisons.
We have not verified manufacturing costs or the manufacturer's margin. We also do not use a Japanese retailer's exclusive-pack listing as a direct same-product international price comparison. A shared brand and tablet count are insufficient when the exact SKU, market conditions and other costs have not been matched.
If you are comparing purchase options, check the actual pack, ingredient denominator, shipping terms and current total price. A larger bottle is not automatically better value without verified prices for the alternatives. Nor does a lower unit price resolve a missing piece of product-specific evidence.
The figure here is a dated snapshot, not a promise of future pricing. The current product listing is the place to check the latest bottle price and package information before ordering.
6. What to check before deciding whether this product fits
An informed decision starts with the actual package and your circumstances—not a headline borrowed from a different study. Check the label directions, the ingredient list and the storage instructions. If you are already receiving medical care, the manufacturer's insert advises consultation with an appropriate professional before use. That is a specific label precaution, not something that can be replaced by a graph or a company timeline. [4]
Swipe to compare →
| Check | Why it matters | Where to look |
|---|---|---|
| Exact package | Brand name alone does not identify a preparation or pack size. | The bottle, box and current product listing. |
| Ingredient denominator | The 270 mg figure applies to nine tablets. | The manufacturer's ingredient table. |
| Other ingredients | The published list includes lactose hydrate and other tablet ingredients. | The complete ingredient list and any relevant professional advice. |
| Directions and consultation advice | The label distinguishes age groups and advises consultation for people receiving medical care. | The insert supplied with the product, rather than a study regimen. |
| Storage and expiry | The insert specifies a tightly closed container, a cool dry place and avoidance of direct sunlight; it advises against transferring containers or using an expired product. | The manufacturer's handling instructions and your package's expiry information. |
A few common questions
Does a 330-tablet bottle contain more concentrated material than a smaller pack?
The count identifies package quantity, not concentration per tablet. The manufacturer's pack list alone does not support interpreting a larger bottle as a more concentrated preparation.
Can I estimate CFU from the 270 mg figure?
No. The retail insert examined here gives powder mass but no CFU figure. A viable count would need preparation-specific information and an applicable measurement method.
Does a Japanese study make the retail product a closer evidence match?
Not by location alone. The 2020 cohort came from Kumamoto University Hospital in Japan, while the 2025 trial was conducted in Taiwan. What matters is the exact preparation, people, comparison and outcome—not the nationality of a brand or research team. [5] [6]
What would close the gap between research and this bottle?
A direct study of the identified retail preparation, or a sufficiently documented match of identity, composition, viable amount and relevant conditions, would address questions that the sources reviewed here leave open. A familiar name alone cannot do that work.
Miyarisan's history and clearly documented label make this product an interesting example of Japanese bacterial-product manufacturing. They also provide a useful lesson in reading evidence carefully: history establishes background, the label establishes disclosed composition, and a human study establishes findings only within its particular methods and setting.
If you want to inspect the package discussed throughout this guide, our Miyarisan Strong 330-tablet page brings together its current price, product images and ingredient details. Use that listing to review the exact item, while keeping the research distinctions above in mind.
Sources and scope
Manufacturer sources describe the company and its label; the three human papers are selected examples for examining research methods. This is not a systematic review, a personal-use recommendation or a U.S. regulatory assessment. Sources and the retail price were checked on October 8, 2026.
- Miyarisan Pharmaceutical: official company profile and corporate timeline.
- Miyarisan Pharmaceutical: official English profile and bacterial naming.
- Strong Miyarisan tablets: official product information and pack sizes.
- Strong Miyarisan tablets: manufacturer-provided Japanese package insert.
- Wang and colleagues, 2025: randomized CBM588 crossover paper. See methods, participant flow, analysis populations and disclosures. DOI: 10.32604/or.2025.070432.
- 2020 CBM588 retrospective clinical cohort at Kumamoto University Hospital: 118 participants; study design and cohort description.
- 2018 randomized, open-label CBM588 adjunctive study: 40 participants, 20 per group; design and limitations. DOI: 10.1097/WNF.0000000000000299.
